The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement - Episode 8

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

,

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

EP. 1: AL Amyloidosis: Background, Patient Profile, and Staging
EP. 2: Navigating the Differential Diagnosis of AL Amyloidosis
EP. 3: Treatment Approaches in AL Amyloidosis
EP. 4: Limitations of Available Treatment Options for Patients with Cardiac Involvement
EP. 5: Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial
EP. 6: Birtamimab Safety Profile in the VITAL Study
EP. 7: Adverse Event Management in AL Amyloidosis
Now Viewing
EP. 8: Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment
EP. 9: Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches
EP. 10: Clinical Pearls and Future Directions in AL Amyloidosis